Dominique-Laurent Couturier

Oct 16, 2023 | nature.com | Carolin M Sauer |James Hall |Dominique-Laurent Couturier |Thomas Bradley |Ashley Sawle |Matthew Eldridge | +6 more

AbstractHigh-grade serous ovarian carcinoma (HGSOC) is characterised by poor outcome and extreme chromosome instability (CIN). Therapies targeting centrosome amplification (CA), a key mediator of chromosome missegregation, may have significant clinical utility in HGSOC. However, the prevalence of CA in HGSOC, its relationship to genomic biomarkers of CIN and its potential impact on therapeutic response have not been defined.